At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGTX Cognition Therapeutics, Inc
Post-Mkt 03-10 19:33:12 EDT
1.12
+0.04
+3.70%
盘后1.15
+0.03+2.68%
18:51 EDT
High1.18Low1.08Vol839.47K
Open1.09D1 Closing1.08Amplitude9.25%
Mkt Cap98.87MTradable Cap98.25MTotal Shares88.27M
T/O952.61KT/O Rate0.96%Tradable Shares87.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
TIPRANKS  ·  03-04
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
Cognition Therapeutics Advancing Zervimesine (Ct1812) for Dementia With Lewy Bodies (Dlb) Psychosis
THOMSON REUTERS  ·  03-02
Cognition Therapeutics Advancing Zervimesine (Ct1812) for Dementia With Lewy Bodies (Dlb) Psychosis
Cognition - to Meet FDA Division of Psychiatry to Discuss a Dlb Psychosis Program by Midyear 2026
THOMSON REUTERS  ·  03-02
Cognition - to Meet FDA Division of Psychiatry to Discuss a Dlb Psychosis Program by Midyear 2026
Cognition Therapeutics Plans Registrational Development Program for Zervimesine in DLB Psychosis, Including New Randomized Study and FDA Psychiatry Division Meeting by Mid-2026
Reuters  ·  03-02
Cognition Therapeutics Plans Registrational Development Program for Zervimesine in DLB Psychosis, Including New Randomized Study and FDA Psychiatry Division Meeting by Mid-2026
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares
Reuters  ·  02-06
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, FirstCash Holdings, CF Bankshares
BRIEF-Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy Bodies
Reuters  ·  02-05
BRIEF-Cognition Therapeutics Extends Expanded Access Program For Zervimesine (Ct1812) In Dementia With Lewy Bodies
Cognition Therapeutics Completes Type C Meeting With FDA for Zervimesine (Ct1812) in Dementia With Lewy Bodies
THOMSON REUTERS  ·  01-27
Cognition Therapeutics Completes Type C Meeting With FDA for Zervimesine (Ct1812) in Dementia With Lewy Bodies
Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies
Reuters  ·  01-06
Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies
Cognition Therapeutics Inc - Company Terminates Previous Sales Agreement With B. Riley - SEC Filing
THOMSON REUTERS  ·  2025-12-19
Cognition Therapeutics Inc - Company Terminates Previous Sales Agreement With B. Riley - SEC Filing
Cognition Therapeutics: Entered Into Open Market Sales Agreement With Jefferies for Offering of up to $75 Mln Shares of Common Stock
THOMSON REUTERS  ·  2025-12-19
Cognition Therapeutics: Entered Into Open Market Sales Agreement With Jefferies for Offering of up to $75 Mln Shares of Common Stock
Cognition Therapeutics Inc - to Offer up to $300 Mln in Securities - SEC Filing
THOMSON REUTERS  ·  2025-12-19
Cognition Therapeutics Inc - to Offer up to $300 Mln in Securities - SEC Filing
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  2025-12-04
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire  ·  2025-12-03
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease
Reuters  ·  2025-12-01
Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  2025-12-01
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating
MT Newswires Live  ·  2025-11-21
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  2025-11-19
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  2025-11-19
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
Mesoblast Appoints James O'Brien CFO
MT Newswires Live  ·  2025-11-17
Mesoblast Appoints James O'Brien CFO
BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Reuters  ·  2025-11-17
BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division

Introduction

Company Name.
Cognition Therapeutics, Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Issue price:
--